8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A prescriber-level guide to managing adverse events from GIP/GLP-1 dual agonists (tirzepatide), covering nausea, pancreatitis, gastroparesis, hypoglycemia, and injection-site reactions with dose titration protocols and monitoring schedules.
A prescriber-level guide to billing codes, prior authorization strategy, step therapy, and appeal tactics for tirzepatide and the GIP/GLP-1 dual agonist class. Includes real trial data, dose thresholds, and ICD-10 documentation requirements.
A comprehensive drug-drug interaction table and prescribing guide for GIP/GLP-1 dual agonists (tirzepatide class), written at MD/PharmD level with primary-source citations.
A clinical-depth prescriber guide to monitoring GIP/GLP-1 dual agonists (tirzepatide). Covers baseline workup, ongoing labs, adverse-event thresholds, and special populations. prepared by the HealthRX.com Editorial Team.
A clinician-level guide to tirzepatide titration schedules, dose-escalation pacing, GI tolerability management, and evidence-based tapering strategies for GIP/GLP-1 dual agonists.
A prescriber-level monograph covering the pharmacology, clinical trial data, dosing, safety, and approved indications for GIP/GLP-1 dual agonists, with tirzepatide as the class prototype.
A prescriber-level guide to GIP/GLP-1 dual agonists covering mechanism, agent selection, dosing, trial data, and clinical decision-making for weight loss, T2D, sleep apnea, and HFpEF.
Evidence-based prescribing guide for tirzepatide and other GIP/GLP-1 dual agonists in renal impairment, hepatic disease, older adults, adolescents, pregnancy, and heart failure with preserved ejection fraction.